daxor corpor dxr buy pt pump volum blood volum analysi pioneer may chang standard
initi coverag buy pt analyst anthoni vendetti full summari
cullen/frost banker inc buy pt ep match consensu nim pressur lower estim pt
 still buy growth outlook analyst michael diana full summari
 buy pt nim pressur els best-in-class lower pt reiter
buy base growth outlook analyst michael diana full summari
chicken soup soul entertain inc csse buy pt preview expect quarter
contribut crackl reiter buy pt analyst allen klee cfa full summari
custom inc buy pt miss chang thesi success transform
reiter buy rate price analyst michael diana full summari
inc buy pt preview expect improv retail updat blockchain invest
corpor event call maxim salesperson inform
inc artl cover mccarthi ndr nyc presid ceo gregori gorga wed jul
cover sullivan ndr san francisco cfo david black tue aug
cover sullivan ndr denver cfo david black wed aug
coffe hold co inc jva cover ndr boston ceo andi gordon tue sep
corpor cover ndr boston ceo john miller svp robert verostek
livexl media inc cover klee ndr san francisco ceo rob ellin mon jul
pump volum blood volum analysi pioneer
may chang standard initi coverag
daxor substanti commerci opportun devic provid
accur quick measur blood volum
accur measur blood volum critic treat diagnos
numer ailment heart kidney failur hypertens syncop
fluid blood transfus manag
highli compel data readmiss rate mortal reduct hit
sweet spot better health outcom greater profit
hospit payer
substanti market opportun believ signific commerci
opportun accur devic measur blood volum much faster
current standard care sinc blood volum derang associ
varieti medic surgic condit potenti market larg
use diagnos treat patient heart failur kidney failur
hypertens syncop aid fluid blood transfus manag
critic care unit also use aid diagnosi
treatment disord red blood cell volum includ polycythemia anemia
aid pre-surg evalu red blood cell volum signific
market daxor blood volum measur equip consist roughli
hospit radiolog imag center unit state addit may
intern market potenti user blood volum
measur approv test six separ code reimburs
obtain numer insur compani includ medicar
measur blood volum use reimburs rate great
import hospit decis use inpati use
superior product offer well establish clinic assess blood
volum use physic examin simpl blood test hematocrit
hemoglobin measur frequent inaccur surrog measur blood
volum daxor measur blood volum accuraci
minut substanti faster accur less complex prior
method directli measur blood volum
experienc manag team daxor ceo chairman michael feldschuh
serv compani board director six year assum current
role serv execut team sinc michael year
experi wall street medic field serv manag director
portfolio manag six year manag director
millennium partner eight year addit lead hedg fund aristarc
capit michael began career shaw co new york
compel valuat arriv price target per share use
dcf discount rate termin growth rate revenu forecast
assum dxr adopt us hospit termin year
therefor potenti upsid price target blood volum measur
use dxr becom standard care wide adopt among
click full note
preview expect improv retail updat
expect revenu decreas y/i due tough retail
comparison howev expect signific improv adjust
ebitda loss loss prior year
focus improv perform retail progress tzero roll
data point contract win medici portfolio
forecast revenu declin single-digit growth
retail improv blockchain invest start contribut
overal result expect loss moder annual shift
profit
compani end net cash per share look
call updat expect invest privat equiti firm
current trade revenu versu peer
group trade pt base dcf analysi
equat ev/revenu target
expect loss start moder shift focu retail
profit due earli august expect revenu declin
due tough comparison last year sale market spend
still elev level encourag improv retail segment
account revenu manag get benefit
technolog spend reduc improv search engin optim seo
privat label manag twice rais annual retail segment guidanc
ebitda project overal compani
adjust ebitda loss versu non-gaap loss per
share versu prior year quarter expect minim revenu
contribut high loss blockchain busi slowli
improv tzero result conserv expect medici aggreg gener
loss modestli greater retail gain next five year given earli natur
invest materi contract win could provid upsid estim
result project revenu growth singl digit next five year
narrow loss year reach profit adjust ebitda
non-gaap ep turn
signific upsid estim medici portfolio
becom success manag reduc segment relat loss
medici repres portfolio earli stage ventur invest blockchain
busi posit side busi titl
vote appear gain traction revenu possibl howev given
earlier natur invest possibl accur project
revenu earn could next five year expect continu
aggress invest segment loss exceed profit
retail segment could upsid estim project prove
success believ titl best opportun given pilot program
negoti progress sign deal relat capit zambia degre
loss segment larg manag control base much
decid invest view
conserv balanc sheet allow compani fund next
month compani end net cash per share
anticip addit proce stock sale come
compani discuss privat equiti firm potenti invest
tzero majority-own subsidiari compani move cloud expect
modest capital-expenditure requir go forward project free cash outflow
per share
turn posit per share
flow influenc pace medici invest earli stage ventur
ramp tzero current project loss medici adjust
ebitda basi slightli higher gain retail next five year
thereaft combin segment gener net cash flow note pre-tax
earn support net oper loss nol year-end
see multipl catalyst stock believ investor get
confid retail segment sustain profit pathway toward profit
blockchain invest stock valuat improv potenti catalyst
potenti sale retail segment
better expect profit retail better outlook rel
potenti invest makara possibl gsr privat equiti firm
pick-up trade crypto wallet due higher volum bitcoin etherium
newli launch mobil app crypto trade app current avail io
android expect shortli big player busi garner high
sign secur token offer trade tzero believ compani
sign around five get sign investor get greater
confid market opportun tzero alreadi announc letter intent
token commerci real-est partner token atari movi
addit dinosaur financi group ad particip broker dealer
clear firm
approv retail broker-deal subsidiari new member applic current
review
tzero secur token becom avail trade non-accredit investor
boston secur exchang jv go live subject sec approv
sign land titl deal new vote contract relat medici invest
full roll digit locat offer tzero public secur
improv crypto market market gone cycl initi
euphoria along bad player signific pullback
start recov possibl start phase similar internet
better busi model emerg thrive
potenti short cover short interest either share avail
borrow interest cost
reiter buy rate pt current trade
revenu versu peer group median valu stock base
year dcf analysi util weight averag cost capit wacc
termin growth rate equat ev/revenu target
believ valuat discount reflect liquid concern competit abil retail
abl evalu blockchain invest given recent capit rais
expect retail shift posit cash flow believ ostk
financi condit improv upcom data point blockchain invest
increas investor confid posit outlook reflect larg market
opportun mani shot goal pursu blockchain
click full note
chicken soup soul
preview expect quarter
contribut crackl reiter buy pt
expect focu stream video chicken soup
combin offer soni crackl one
largest advertising-bas vod avod offer market
half quarter crackl jv focu
compani integr oper action bring content
stream site
believ market yet recogn earn potenti
compani improv cost structur crackl opportun
get better advertis volum price improv margin
forecast revenu growth
believ could upsid estim csse continu make
stock trade ev/ebitda multipl forecast
price target base ebitda estim support
analysi
csse transit focu attract area stream media
crackl jv soni sne nr close may project
doubl revenu make csse one largest avod player
market million monthli activ user close advertis sold
network includ avod market attract growth outlook
stream media peg compound-annual-growth-rate csse focus jv cost
cut origin content market technolog cost result jv post
pro forma ebitda margin significantli better like money-
lose situat time purchas compani well-posit becom
natur consolid smaller site gener enough traffic advertis
dollar stand-alone basi channel check major advertis compani
confirm look spread campaign across site
provid signific reach pay higher rate expect css growth
supplement tv seri movi busi along distribut
project high growth rate css current collect asset
like upsid new acquisit deliv sequenti improv
result inclus half quarter crackl jv despit part
season slower year quarter expect result
releas second week august project revenu consensu
y/i adjust ebitda consensu
could upsid forecast consensu estim depend
time tv product get recogn project revenu ebitda
cagr respect crackl jv along growth tv
movi product distribut compani stellar track record identifi
synergist accret acquisit new announc could like add
upsid current high growth rate project
believ css stock still rel undiscov trade discount
growth rate peer group csse stock trade ebitda
price target base ebitda peer median
use higher multipl peer due csse faster project
growth rate adjust ebitda margin peer also credit manag
excel track record alloc capit area grown revenu
profit believ csse repres uniqu opportun buy rel small
compani strong brand growth prospect
click full note
